Search results
Results from the WOW.Com Content Network
In 2019, Winship Cancer Institute was awarded a five-year, $9.7 million Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute, the first grant of its kind to be awarded in the state of Georgia, to study new approaches for lung cancer treatment. [8]
Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]
Approximately 98% of lung cancers are carcinoma, a term describing malignancies derived from transformed cells exhibiting characteristics of epithelium. About 2% of all lung cancers are non-carcinoma (mainly sarcoma, tumors of hematopoietic origin, or germ cell tumors. [5] These forms of lung cancer are usually treated differently from carcinomas.
Dr. Slocum at the Freeman Health System Lung Institute says a low-dose chest CT scan is a rapid test looking for nodules. “At least 97% of the initial nodules that we see are not going to be ...
The family of Georgia Cancer Center researcher Yan Cui, PhD, is one of many affected by cancer. “My father died of lung cancer in China 30 years ago. As a non-smoker, the cause of his cancer was ...
In spring 2023, Gibbon, who recently turned 69, was told he had advanced stage lung cancer. Lung cancer is the leading cause of cancer deaths in the U.S. by a long shot, accounting for about 1 in ...
The main treatment arms of phase 3 clinical trials providing immunotherapy in the first line for patients with non-small cell lung cancer. [57] Non-small cell lung cancer (NSCLC) cells expressing programmed death-ligand 1 (PD-L1) could interact with programmed death receptor 1 (PD-1) expressed on the surface of T cells, and result in decreased ...
There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers. [ 1 ] [ 3 ] [ 4 ] Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy.